Investigational drug · Phase 3
BCD-217
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Melanoma Stage III, Melanoma (Skin), Melanoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 8, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "BCD-217"
First trial start
2022
Aug 2, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BCD-217", any sponsor or status.
Conditions studied
As listed on its trial records.
- Melanoma Stage III
- Melanoma (Skin)
- Melanoma
- Melanoma Stage IV
- Melanoma Unresectable
- Melanoma Metastatic
- Melanoma Advanced
Approved drugs for the same conditions: Melanoma · Oncology · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "BCD-217" as an intervention, largest first.
- A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin MelanomaPivotal-lookingActive, not recruiting
BiocadIndustry
NCT05751928 · 411 participants · Start Apr 5, 2023 · Primary completion Jan 2027
Drug: BCD-217; anti-PD1 · For: Melanoma Stage III; Melanoma (Skin)
Sites: Lesnoy, Belarus; Minsk, Belarus; Mogilev, Belarus · 36 sites in all
- A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic MelanomaPivotal-lookingActive, not recruiting
BiocadIndustry
NCT05732805 · 270 participants (planned) · Start Aug 2, 2022 · Primary completion Jun 20, 2024
Drug: BCD-217; BCD-100 and 1 more · For: Melanoma; Melanoma (Skin); Melanoma Stage III and 4 more
Sites: Babruysk, Belarus; Brest, Belarus; Grodno, Belarus · 63 sites in all
- Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic MelanomaPivotal-lookingStatus unknown
BiocadIndustry
NCT03913923 · 117 participants · Start Jul 1, 2019 · Primary completion Jul 2023
Drug: BCD-217; BCD-100 · For: Melanoma; Melanoma Metastatic
Sites: The Settlement of Lesnoy, Belarus; Minsk, Belarus; Sochi, Russia · 23 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial.
Demidov L, Samoylenko I, Kharkevich G, et al. · Eur J Cancer 2025
Also in development for Melanoma Stage III
- L19TNFL19IL2, OnfekafuspPhase 310 trials
Philogen S.p.A. · Glioblastoma, Locally Advanced Basal Cell Carcinoma, Melanoma Stage III
- prolgolimabBCD-100, FortecaPhase 31 trial
Biocad · Melanoma, Melanoma (Skin), Melanoma Stage III
- DNA VaccinePhase 22 trials
NEC Bio B.V · Triple Negative Breast Cancer, Malignant Melanoma, Melanoma (Skin)
- KB707Phase 22 trials
Krystal Biotech, Inc. · Cancer, Melanoma Stage III, Melanoma Stage IV
- PRTX007Phase 21 trial
Primmune Therapeutics, Inc. · Melanoma Stage III
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.